8-K
filed June 14, 2023, 7:59 PM ET
ticker PRAX
CIK 0001689548
other material
confidence high
sentiment neutral
materiality 0.15
Stockholders elect three directors, ratify auditor, approve executive compensation at 2023 annual meeting
Praxis Precision Medicines, Inc.
- Gregory Norden, Marcio Souza, and William Young elected as Class III directors; Young received 18.4M for, 24.1M withheld.
- Ratification of Ernst & Young as independent auditor for fiscal 2023 passed with 47.6M for, 18,327 against.
- Advisory vote on named executive officer compensation approved with 29.8M for, 7.7M against, 1.0M abstain.
- Broker non-votes: 5.2M on director election and say-on-pay proposals; none on auditor ratification.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Praxis Precision Medicines, Inc. shareholders approved Election of Class III Directors at the 2023-06-12 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-12
Exact text from the filing
Proposal 1 – Election of Class III Directors The Company’s stockholders elected Gregory Norden, Marcio Souza and William Young to serve as Class III members of the Board of Directors of the Company (the “Board”) until the Company’s 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal, with the votes cast as follows: Class III Director Nominees Votes For Votes Withheld Broker Non-Vote Gregory Norden 35,093,179 7,366,080 5,199,545 Marcio Souza 35,151,003 7,308,256 5,199,545 William Young 18,353,865 24,105,394 5,199,545
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Praxis Precision Medicines, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-06-12 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-12
Exact text from the filing
Proposal 3 – Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 29,790,931 7,738,170 1,033,594 5,199,545
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Praxis Precision Medicines, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm at the 2023-06-12 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-12
Exact text from the filing
Proposal 2 – Ratification of Appointment of Ernst & Young LLP as the Company ’ s Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Vote 47,578,569 18,327 61,908 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.